Heartbeam (BEAT) Q2 2024 earnings summary

Executive summary

• AIMIGo, a credit card-sized, cable-free 12-lead ECG device, is under active FDA review, with a limited launch anticipated by year-end 2024; a second 510(k) for 12-lead synthesis software is in preparation.

• The technology leverages proprietary vector technology and advanced AI algorithms, showing superior arrhythmia detection compared to single-lead ECG and expert panels.

• Clinical studies, including VALID-ECG (over 500 patients, 7,500+ recordings), completed enrollment and demonstrated equivalence to traditional 12-lead ECG for arrhythmia and coronary occlusion detection.

• AIMIGo targets arrhythmia detection initially, with plans to expand into heart attack detection and chronic disease monitoring.

• Company received industry recognition, including a MedTech Breakthrough Award and Russell Microcap Index inclusion.

Financial highlights

• Net loss for Q2 2024 was $5.0 million, up from $3.2 million in Q2 2023; operating expenses rose to $5.09 million, driven by higher R&D and G&A costs.

• Research and development expenses increased to $2.8 million from $1.5 million year-over-year.

• General and administrative expenses rose to $2.2 million from $1.8 million year-over-year.

• Cash and cash equivalents as of June 30, 2024, were $9.2 million, down from $16.2 million at year-end 2023.

• Net cash used in operating activities for the first half of 2024 was $7.0 million.

Outlook and guidance

• Limited AIMIGo launch is planned by end of 2024, pending FDA clearance, with feedback from real-world use.

• Preparing a second FDA 510(k) submission for the algorithm that synthesizes 12-lead ECG from vector signals.

• No significant commercial revenue is expected in 2024; future operations depend on additional capital raises or partnerships.

• Existing cash is insufficient to fund operations for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.

• Product pipeline includes an extended wear patch for heart attack and arrhythmia detection, targeting a $4.8 billion market by 2030.